MX2022009654A - Receptor de células t restringido por hla de la clase i contra ras con mutación g12d. - Google Patents
Receptor de células t restringido por hla de la clase i contra ras con mutación g12d.Info
- Publication number
- MX2022009654A MX2022009654A MX2022009654A MX2022009654A MX2022009654A MX 2022009654 A MX2022009654 A MX 2022009654A MX 2022009654 A MX2022009654 A MX 2022009654A MX 2022009654 A MX2022009654 A MX 2022009654A MX 2022009654 A MX2022009654 A MX 2022009654A
- Authority
- MX
- Mexico
- Prior art keywords
- mutation
- restricted
- hla class
- cell receptors
- tcr
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 4
- 230000035772 mutation Effects 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 235000003704 aspartic acid Nutrition 0.000 abstract 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 150000002333 glycines Chemical group 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000003259 recombinant expression Methods 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/00041—Use of virus, viral particle or viral elements as a vector
- C12N2740/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
Abstract
Se describe un receptor de células T (TCR) aislado y purificado, donde el TCR tiene especificidad antigénica por una secuencia de aminoácidos RAS humana mutada con una sustitución de glicina en la posición 12 con ácido aspártico presentada por una molécula de antígeno leucocitario humano (HLA) de la Clase I. También se proporcionan polipéptidos y proteínas relacionadas, así como los ácidos nucleicos relacionados, vectores de expresión recombinantes, células anfitrionas, poblaciones de células y composiciones farmacéuticas. También se describen métodos para detectar la presencia de cáncer en un mamífero y métodos de tratamiento y prevención del cáncer en un mamífero.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975544P | 2020-02-12 | 2020-02-12 | |
| PCT/US2021/017794 WO2021163434A1 (en) | 2020-02-12 | 2021-02-12 | Hla class i-restricted t cell receptors against ras with g12d mutation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009654A true MX2022009654A (es) | 2022-10-20 |
Family
ID=74860472
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009654A MX2022009654A (es) | 2020-02-12 | 2021-02-12 | Receptor de células t restringido por hla de la clase i contra ras con mutación g12d. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230080742A1 (es) |
| EP (1) | EP4103597A1 (es) |
| JP (1) | JP2023528112A (es) |
| KR (1) | KR20220143867A (es) |
| CN (1) | CN115279784A (es) |
| AU (1) | AU2021221138A1 (es) |
| BR (1) | BR112022015888A2 (es) |
| CA (1) | CA3168015A1 (es) |
| CL (1) | CL2022002208A1 (es) |
| CO (1) | CO2022012922A2 (es) |
| CU (1) | CU20220044A7 (es) |
| GB (1) | GB2609760A (es) |
| IL (1) | IL295252A (es) |
| MX (1) | MX2022009654A (es) |
| TW (1) | TW202140536A (es) |
| WO (1) | WO2021163434A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021351710A1 (en) * | 2020-10-02 | 2023-06-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class ii-restricted dq t cell receptors against ras with g13d mutation |
| WO2022183167A1 (en) | 2021-02-25 | 2022-09-01 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004021995A2 (en) | 2002-09-06 | 2004-03-18 | The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| JP6863893B2 (ja) * | 2014-11-26 | 2021-04-21 | アメリカ合衆国 | 抗突然変異ｋｒａｓ ｔ細胞受容体 |
| CN108395479B (zh) * | 2017-02-06 | 2021-07-16 | 高军 | 一种有关kras基因突变的t细胞受体 |
| CA3084246A1 (en) * | 2017-12-04 | 2019-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hla class i-restricted t cell receptors against mutated ras |
-
2021
- 2021-02-12 CA CA3168015A patent/CA3168015A1/en active Pending
- 2021-02-12 GB GB2211733.7A patent/GB2609760A/en active Pending
- 2021-02-12 KR KR1020227031175A patent/KR20220143867A/ko unknown
- 2021-02-12 AU AU2021221138A patent/AU2021221138A1/en active Pending
- 2021-02-12 US US17/799,163 patent/US20230080742A1/en active Pending
- 2021-02-12 MX MX2022009654A patent/MX2022009654A/es unknown
- 2021-02-12 IL IL295252A patent/IL295252A/en unknown
- 2021-02-12 WO PCT/US2021/017794 patent/WO2021163434A1/en unknown
- 2021-02-12 CU CU2022000044A patent/CU20220044A7/es unknown
- 2021-02-12 JP JP2022548811A patent/JP2023528112A/ja active Pending
- 2021-02-12 EP EP21710730.9A patent/EP4103597A1/en active Pending
- 2021-02-12 BR BR112022015888A patent/BR112022015888A2/pt unknown
- 2021-02-12 TW TW110105194A patent/TW202140536A/zh unknown
- 2021-02-12 CN CN202180014038.2A patent/CN115279784A/zh active Pending
-
2022
- 2022-08-12 CL CL2022002208A patent/CL2022002208A1/es unknown
- 2022-09-12 CO CONC2022/0012922A patent/CO2022012922A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115279784A (zh) | 2022-11-01 |
| WO2021163434A1 (en) | 2021-08-19 |
| BR112022015888A2 (pt) | 2022-10-11 |
| IL295252A (en) | 2022-10-01 |
| CA3168015A1 (en) | 2021-08-19 |
| WO2021163434A8 (en) | 2022-09-01 |
| US20230080742A1 (en) | 2023-03-16 |
| GB202211733D0 (en) | 2022-09-28 |
| EP4103597A1 (en) | 2022-12-21 |
| GB2609760A (en) | 2023-02-15 |
| JP2023528112A (ja) | 2023-07-04 |
| CL2022002208A1 (es) | 2023-06-02 |
| CU20220044A7 (es) | 2023-06-13 |
| KR20220143867A (ko) | 2022-10-25 |
| TW202140536A (zh) | 2021-11-01 |
| CO2022012922A2 (es) | 2022-10-21 |
| AU2021221138A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005765A (es) | Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado. | |
| MX2022009654A (es) | Receptor de células t restringido por hla de la clase i contra ras con mutación g12d. | |
| MX2022009825A (es) | Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v. | |
| MX2022010157A (es) | Receptores de células t restringidos a hla clase ii contra ras con mutación g12v. | |
| Spies et al. | Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer | |
| EA202090652A1 (ru) | T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras | |
| CR20200170A (es) | Receptores de células t que reconocen p53 mutado | |
| MX2021015877A (es) | Receptores de celulas t que reconocen la mutacion r175h o y220c en p53. | |
| EP3412680A2 (en) | Novel peptides that bind to types of mhc class ii and their use in diagnosis and treatment | |
| MX2019009641A (es) | Receptores de la celula t que reconocen mhc de mage-a3 de clase ii-restringida. | |
| WO2008089053A3 (en) | Gp100-specific t cell receptors and related materials and methods of use | |
| KR20030084992A (ko) | 감소된 면역원성을 갖는 개질 인터페론 베타 | |
| Zou et al. | Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic analysis | |
| Celis et al. | Genetic restriction and fine specificity of human T cell clones reactive with rabies virus. | |
| JP2004535173A (ja) | 低減された免疫原性を有する修飾されたインターフェロンアルファ | |
| Zhang et al. | A COVID-19 T-cell response detection method based on a newly identified human CD8+ T cell epitope from SARS-CoV-2—Hubei province, China, 2021 | |
| WO2022015694A8 (en) | Hla class ii–restricted drb t cell receptors against ras with g12d mutation | |
| Schmidt et al. | Serological and immunochemical studies of H‐2 allospecificities on K36, a syngeneic tumour of AKR | |
| WO2021262829A3 (en) | Hla class i-restricted t cell receptors against cd20 | |
| Atassi et al. | Immune recognition of serum albumin—XIV. Cross-reactivity by T-lymphocyte proliferation of subdomains 3, 6 and 9 of bovine serum albumin | |
| WO2022051449A3 (en) | T cell receptors recognizing r273c or y220c mutations in p53 | |
| Maryanski et al. | Structural features of peptides recognized by H-2Kd-restricted T cells | |
| CN109456405B (zh) | 一种去棕榈酰化pd-l1蛋白质及其制备方法和应用 | |
| CN113105528A (zh) | 一条肿瘤相关抗原ctl表位肽及其应用 | |
| Brackenridge et al. | Mapping the epitopes of the Human Leukocyte Antigen E antibodies 3D12 and 4D12 |